MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN) from its SEC filings: 2025 revenue $824.5 million (-2% vs the year before), net margin -44%, free cash flow $1.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Revenue (2025) | $824.5 million |
| Revenue growth | -2% |
| Net income | -$366.0 million |
| Net margin | -44.4% |
| Free cash flow | $1.8 million |
| Diluted EPS | $-3.95 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -10% |
| Cash | $115.2 million |
| Long-term debt | $120.7 million |
| Share count, 1 year | +3% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.